Gillespie M T, Thomas R J, Pu Z Y, Zhou H, Martin T J, Findlay D M
St. Vincent's Institute of Medical Research and The University of Melbourne, Department of Medicine, St. Vincent's Hospital, Fitzroy, Victoria, Australia.
Int J Cancer. 1997 Dec 10;73(6):812-5. doi: 10.1002/(sici)1097-0215(19971210)73:6<812::aid-ijc7>3.0.co;2-5.
Several human breast cancer cell lines express the calcitonin receptor (CTR), but this has not been demonstrated previously in clinical breast cancers. We examined 18 primary breast cancers by reverse transcription-PCR, for expression of CTR and of the bone proteins osteopontin (OPN) and bone sialoprotein (BSP). OPN and CTR were expressed by each of the tumours, and 7 (39%) additionally expressed an alternate form of CTR, whilst BSP was expressed by 13 tumours (72%). In situ hybridisation confirmed that expression of OPN and CTR was confined to the tumour cells. Expression of CTR, BSP and OPN may prove to be a useful marker for breast cancers, and their role in the homing of breast cancer cells to bone remains to be investigated.
几种人乳腺癌细胞系表达降钙素受体（CTR），但此前尚未在临床乳腺癌中得到证实。我们通过逆转录聚合酶链反应检测了18例原发性乳腺癌，以检测CTR以及骨蛋白骨桥蛋白（OPN）和骨唾液酸蛋白（BSP）的表达。每个肿瘤均表达OPN和CTR，7例（39%）还表达了CTR的一种替代形式，而13例肿瘤（72%）表达BSP。原位杂交证实OPN和CTR的表达局限于肿瘤细胞。CTR、BSP和OPN的表达可能被证明是乳腺癌的一个有用标志物，它们在乳腺癌细胞归巢至骨中的作用仍有待研究。
